← All trials
NCT05564286
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2021
- Primary completion
- Jul 31, 2024
- Completion date
- Sep 30, 2024
- First posted
- Oct 3, 2022
- Last posted
- Oct 3, 2022
- Enrollment
- 206
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shantou UniversityLead sponsor
- Shantou UniversityOverall official - principal investigator
- Shantou UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.